Purpose: The aim of this study was to investigate the effects of quercetin on vascular endothelial growth factor (VEGF)-induced choroidal and retinal angiogenesis in vitro using a rhesus macaque choroid-retinal endothelial (RF/6A) cell line. Methods: RF/6A cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Then the cells were treated with different concentrations (from 0 to 100 μM) of quercetin and 100 ng/ml VEGF. The cell proliferation was assessed using cholecystokinin octapeptide dye. The cell migration was investigated by a Transwell assay. The tube formation was measured on Matrigel. Furthermore, the impact of quercetin's effects on VEGF-induced activation of VEGF receptor 2 (VEGFR-2) downstream signal pathways was tested by Western blot analysis. Results: Quercetin inhibits RF/6A cell proliferation in a dose-dependent fashion: 22.7, 31.5 and 36.7% inhibition on treatment with 10, 50 and 100 μM quercetin, respectively. VEGF-induced migration and tube formation of RF/6A cells were also significantly inhibited by quercetin in a dose-dependent manner. Quercetin inhibits VEGF-induced VEGFR-2 downstream signal pathways of RF/6A. Conclusions: The results show that quercetin inhibits VEGF-induced cell proliferation, migration and tube formation of RF/6A. We suggest that quercetin inhibits VEGF-induced choroidal and retinal angiogenesis in vitro. Collectively, the findings in the present study suggest that quercetin inhibits VEGF-induced choroidal and retinal angiogenesis by targeting the VEGFR-2 pathway. This suggests that quercetin is a choroidal and retinal angiogenesis inhibitor.

Keywords:
Choroidal and retinal angiogenesis, Rhesus macaque choroid-retinal endothelial (RF/6A) cell line, Quercetin, Vascular endothelial growth factor
1.
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;17;364:603-615.
2.
Aiello LP: Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-135.
3.
De Jong PT: Age-related macular degeneration. N Engl J Med 2006;355:1474-1485.
4.
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann R: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
5.
Gariano RF, Gardner T: Retinal angiogenesis in development and disease. Nature 2005;438:960-966.
6.
Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ, Klaassen I, Schlingemann RO: A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 2012;96:587-590.
7.
Lamson D, Brignall M: Antioxidants and cancer. 3. Quercetin. Altern Med Rev 2000;5:196-208.
8.
Sellappan S, Akoh C: Flavonoids and antioxidant capacity of Georgia-grown Vidalia onions. J Agric Food Chem 2002;50:5338-5342.
9.
Formica JV, Regelson W: Review of the biology of quercetin and related bioflavonoids. Food ChemToxicol 1995;33:1061-1080.
10.
Lee KW, Kim YJ, Kim DO, Lee HJ, Lee CY: Major phenolics in apple and their contribution to the total antioxidant capacity. J Agric Food Chem 2003;51:6516-6520.
11.
Chen Y, Li XX, Xing NZ, Cao XG: Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol 2008;246:373-378.
12.
Perez-Vizcaino F, Duarte J: Flavonols and cardiovascular disease. Mol Aspects Med 2010;31:478-494.
13.
De Boer VC, Dihal AA, van der Woude H, Arts IC, Wolffram S, Alink GM, Rietjens IM, Keijer J, Hollman PC: Tissue distribution of quercetin in rats and pigs. J Nutr 2005;135:1718-1725.
14.
Corvazier E, Maclouf J: Interference of some flavonoids and non-steroidal anti-inflammatory drugs with oxidative metabolism of arachidonic acid by human platelets and neutrophilis. Biochim Biophys Acta 1985;835:315-321.
15.
Havesteen B: Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 1983;32:1141-1148.
16.
Castillo MH, Perkins E, Campbell JH, Doerr R, Hassett JM, Kandaswami C, Middleton E Jr: The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin. Am J Surg 1989;158:351-355.
17.
Rodgers EH, Grant MH: The effect of the flavonoids, quercetin, myricetin and epicatechin on the growth and enzyme activities of MCF 7 human breast cancer cells. Chem Biol Interact 1998;116:213-228.
18.
Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wähälä K, Montesano R, Schweigerer L: Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997;57:2916-2921.
19.
Igura K, Ohta T, Kuroda Y, Kaji K: Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 2001;171:11-16.
20.
Tan WF, Lin LP, Li MH, Zhang YX, Tong YG, Xiao D, Ding J: Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 2003;459:255-262.
21.
Oh SJ, Kim O, Lee JS, Kim JA, Kim MR, Choi HS, Shim JH, Kang KW, Kim YC: Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. Food Chem Toxicol 2010;48:3227-3234.
22.
Zhao D, Qin C, Fan X, Li Y, Gu B: Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur J Pharmacol 2014;723:360-367.
23.
Rousseau S, Houle F, Huot J: Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 2000;10:321-327.
24.
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
25.
Kowanetz M, Ferrara N: Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12:5018-5022.
26.
Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-478.
27.
Byrne AM, Bouchier-Hayes DJ, Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005;9:777-794.
28.
Yu X, Zhu J, Mi M, Chen W, Pan Q, Wei M: Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med Oncol 2012;29:349-357.
29.
Takahashi T, Yamaguchi S, Chida K, Shibuya M: A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLCgamma and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768-2778.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.